ChromoCure, Inc. Launches Nationwide Diagnostic Lab Partnership Program

RENO, NV--(Marketwire - November 03, 2009) -

ChromoCure, Inc. (PINKSHEETS: KKUR) announced its partnership program for cancer diagnostic laboratories and research centers.

Industry pathologists and cancer diagnostic research centers may request the company’s partnership package and materials at:

http://chromocure.com/services/pathology-request/

Pathology labs will receive ChromoCure’s CS200 Chromosomal Scanner installed on their premises without cost. ChromoCure will provide training, material, and marketing guidance. Established insurance codes exist for ease of billing and collections. The ChromoCure CS200 can deliver immediate revenue to pathologists.

Cancer research centers may purchase the company’s equipment or use one of the company’s network pathology labs to perform chromosomal scans. Preferred pricing will be extended to all cancer research partners. Purchasers of the CS200 chromosomal scanner will receive a favorable upgrade price to the CS300 series when released.

The company has established this special program to expand it network of pathology labs as well as promote its science and technology with cancer research centers.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company’s systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

The Company’s technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.